Kosaraju Sridhar 4

What Happened Kosaraju Sridhar, a director of 10x Genomics, received an award of 8,829 restricted stock units (RSUs) on June 4, 2026. The RSUs were granted at a $0.00 acquisition price (i.e., no cash paid by the insider). Each RSU represents a contingent right to receive one share of Class A common stock upon vesting.

Key Details

• Transaction date: 2026-06-04; Form 4 filed: 2026-06-08.
• Transaction type: Award/Grant (Code A) — 8,829 RSUs granted at $0.00 (total reported acquisition value = $0).
• Vesting: Footnote states RSUs vest 1/4th each quarterly anniversary measured from May 21, 2026, subject to continued service (i.e., fully vests after four quarterly vesting events).
• Shares owned after transaction: Not specified in the filing.
• Related holdings: Footnote indicates certain shares are held by the Kosaraju Family Trust dated June 21, 2014, for which the reporting person is trustee.
• Filing exhibits: Exhibit 24.1 (Power of Attorney) attached.

Context This is a grant of restricted stock units (a common form of compensation/retention award for executives and directors). RSUs are not immediate share ownership until they vest; they do not indicate an immediate purchase or sale. The grant price of $0 simply reflects that the RSUs were awarded rather than bought; any market value depends on 10x Genomics’ share price at vesting. The filing appears to have been submitted shortly after the transaction date (Form 4 filed June 8 for a June 4 grant).